GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Asset Turnover

Entheon Biomedical (XCNQ:ENBI) Asset Turnover : 0.00 (As of Aug. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Entheon Biomedical's Revenue for the three months ended in Aug. 2024 was C$0.00 Mil. Entheon Biomedical's Total Assets for the quarter that ended in Aug. 2024 was C$0.29 Mil. Therefore, Entheon Biomedical's Asset Turnover for the quarter that ended in Aug. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Entheon Biomedical's annualized ROE % for the quarter that ended in Aug. 2024 was -99.43%. It is also linked to ROA % through Du Pont Formula. Entheon Biomedical's annualized ROA % for the quarter that ended in Aug. 2024 was -89.04%.


Entheon Biomedical Asset Turnover Historical Data

The historical data trend for Entheon Biomedical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Asset Turnover Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Asset Turnover
Get a 7-Day Free Trial - - - 0.04 0.43

Entheon Biomedical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Entheon Biomedical's Asset Turnover

For the Biotechnology subindustry, Entheon Biomedical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Asset Turnover falls into.



Entheon Biomedical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Entheon Biomedical's Asset Turnover for the fiscal year that ended in Nov. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Nov. 2023 )/( (Total Assets (A: Nov. 2022 )+Total Assets (A: Nov. 2023 ))/ count )
=0.25/( (0.769+0.401)/ 2 )
=0.25/0.585
=0.43

Entheon Biomedical's Asset Turnover for the quarter that ended in Aug. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Aug. 2024 )/( (Total Assets (Q: May. 2024 )+Total Assets (Q: Aug. 2024 ))/ count )
=0/( (0.335+0.249)/ 2 )
=0/0.292
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Entheon Biomedical  (XCNQ:ENBI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Entheon Biomedical's annulized ROE % for the quarter that ended in Aug. 2024 is

ROE %**(Q: Aug. 2024 )
=Net Income/Total Stockholders Equity
=-0.26/0.2615
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.26 / 0)*(0 / 0.292)*(0.292/ 0.2615)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1166
=ROA %*Equity Multiplier
=-89.04 %*1.1166
=-99.43 %

Note: The Net Income data used here is four times the quarterly (Aug. 2024) net income data. The Revenue data used here is four times the quarterly (Aug. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Entheon Biomedical's annulized ROA % for the quarter that ended in Aug. 2024 is

ROA %(Q: Aug. 2024 )
=Net Income/Total Assets
=-0.26/0.292
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.26 / 0)*(0 / 0.292)
=Net Margin %*Asset Turnover
= %*0
=-89.04 %

Note: The Net Income data used here is four times the quarterly (Aug. 2024) net income data. The Revenue data used here is four times the quarterly (Aug. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Entheon Biomedical Asset Turnover Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to treat addiction and substance use disorders.
Executives
Brian Jahns Senior Officer

Entheon Biomedical Headlines

No Headlines